PriceTargets.com logo

Evotec - EVO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.93
  • Forecasted Upside: 32.74%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.47 As of 12/20/2024 06:16 PM ET
▲ +0.07 (1.59%)

This chart shows the closing price for EVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evotec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVO

Analyst Price Target is $5.93
▲ +32.74% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Evotec in the last 3 months. The average price target is $5.93, with a high forecast of $8.00 and a low forecast of $3.80. The average price target represents a 32.74% upside from the last price of $4.47.

This chart shows the closing price for EVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Evotec. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
10/7/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$8.70 ➝ $3.80
8/15/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $8.00
8/8/2024Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
7/29/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $6.00
7/11/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/25/2024HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $11.00
4/12/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
1/18/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
8/31/2023HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $14.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 12 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Evotec logo
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: $4.47
Low: $4.33
High: $4.57

50 Day Range

MA: $4.33
Low: $2.90
High: $5.55

52 Week Range

Now: $4.47
Low: $2.85
High: $12.00

Volume

1,729,498 shs

Average Volume

139,845 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Evotec?

The following Wall Street analysts have issued reports on Evotec in the last year: Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, and Royal Bank of Canada.
View the latest analyst ratings for EVO.

What is the current price target for Evotec?

0 Wall Street analysts have set twelve-month price targets for Evotec in the last year. Their average twelve-month price target is $5.93, suggesting a possible upside of 32.7%. HC Wainwright has the highest price target set, predicting EVO will reach $8.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $3.80 for Evotec in the next year.
View the latest price targets for EVO.

What is the current consensus analyst rating for Evotec?

Evotec currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EVO, but not buy more shares or sell existing shares.
View the latest ratings for EVO.

What other companies compete with Evotec?

Other companies that are similar to Evotec include Lantheus, Legend Biotech, Nuvalent, Blueprint Medicines and Elanco Animal Health. Learn More about companies similar to Evotec.

How do I contact Evotec's investor relations team?

Evotec's physical mailing address is Essener Bogen 7, Hamburg 22419, Germany. The company's listed phone number is 49-40-560-81-0 and its investor relations email address is [email protected]. The official website for Evotec is www.evotec.com. Learn More about contacing Evotec investor relations.